ChromaDex names Jeffrey Himmel CEO

Tuesday, January 24, 2012 08:39 AM

ChromaDex, based in Irvine, Calif., has named Jeffrey Himmel its new CEO. Previous CEO Frank Jaksch will assume the position of chief scientific officer and remain on the ChromaDex board of directors.

Himmel also has agreed to invest $1 million in ChromaDex.

Himmel previously has held positions at Rothschild and Jeffrey Martin, an over-the-counter pharmaceutical company founded by his father, Martin Himmel. He also is the former chairman of The Himmel Group and currently serves as a member of the board of directors of The Consumer Healthcare Products Association.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs